House GOP campaign arm outraises Democrats in second quarter
The House GOP campaign arm brought in $32.3 million in the second quarter of the year, while the House Democratic campaign arm raised $29.1 million in the same period. In June alone, the NRCC raised $18.1 million and the DCCC brought in $12.7 million.
In 2025 so far, the NRCC has raised a total of $69 million, while the DCCC has raised $66 million.
However, the DCCC reported having $39.7 million in the bank, while the NRCC has $37.6 million cash-on-hand.
The NRCC's second quarter haul is a milestone for the committee, which is normally outraised by its Democratic counterpart. The last time the NRCC outraised the DCCC in the first six months and second quarter of an election cycle was 2021.
'While House Republicans build a historical war chest to grow the majority, House Democrats are broke, divided, and hijacked by socialists,' said Mike Marinella, spokesman at the NRCC. 'Donors are slamming the brakes because they know this party is pathetic, aimless, and has no chance of taking back the majority.'
In their own statement, the DCCC noted they have 'the better message, stronger candidates, and necessary resources' to win back the House next year.
'Republicans are running scared because they know they are poised to be rejected by the American people next year,' said DCCC Chair Suzan DelBene (D-Wash.). 'Their support for the Big, Ugly Law is going to cost them the House Majority. It fails to lower costs for everyday Americans and instead rips health care away from millions, threatens funding for rural hospitals, and will lead to higher energy bills – all to pay for tax breaks for the wealthiest few. It's no surprise that it's the least popular piece of legislation of the 21st century,'
The latest numbers from the House committees come as the Republican National Committee (RNC) reported raising $96.4 million during the first six months of the year, while the Democratic National Committee raked in $69.2 million in the same period. The RNC also holds a cash-on-hand advantage of $80.78 million to $15.22 million.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
LucyRx Announces the Acquisition of CerpassRx, Enhancing Clinical Excellence and Expanding Access to Innovative Healthcare Solutions
This strategic move brings together industry leading service with modern, member-first prescription care. BETHESDA, Md., July 31, 2025--(BUSINESS WIRE)--LucyRx, a fast-scaling, next-generation pharmacy benefits manager (PBM) known for simplifying and improving access to prescription care, has signed a definitive agreement to bring CerpassRx into the LucyRx organization. The combination brings together CerpassRx's proven track record of exceptional service and cost containment with LucyRx's technology-driven clinical approach, all under a shared vision for smarter, more transparent prescription care. CerpassRx is a division of Nomi Health, a direct healthcare company. The transaction is subject to regulatory approvals and customary closing conditions and is expected to close in Q3 2025. By combining LucyRx's technology-driven clinical model with CerpassRx's service-first approach and cost containment expertise, this partnership creates a more impactful PBM solution - one that delivers smarter care, stronger savings, and a seamless experience for clients and members alike. Distinct Strengths. Shared Mission. Greater Value. LucyRx and CerpassRx bring distinct but highly complementary capabilities to this new chapter. LucyRx offers a proprietary Formulary Marketplace, a broad Connected Specialty Care Network that integrates leading health systems and specialty pharmacies, and personalized clinical guidance through its Care Guide model. Its clinical programs focused on high-impact areas like GLP-1 therapies and Women's Health deliver smarter, more proactive prescription care for members. CerpassRx excels in driving down prescription costs through proprietary cost containment strategies, flexible formulary design, and tailored clinical programs. With a high-touch service model, it delivers rapid implementation and measurable outcomes, earning a reputation for disrupting the traditional PBM model and building long-term trust with clients and members. Together, they form a national PBM platform that is performance-driven, clinically forward, and relentlessly focused on serving clients and members with clarity and accountability. A More Impactful Platform for Clients and Members Smarter Cost Containment: CerpassRx's proven cost-saving programs layered onto LucyRx's transparent pricing and formulary marketplace. Stronger Member Support: Integrated clinical teams, anchored by LucyRx's Care Guides and CerpassRx's personalized service culture. Scalable Innovation: LucyRx's AI-powered insights and infrastructure amplify CerpassRx's high-touch service, making care more personal at scale. "CerpassRx is a strong cultural and strategic fit for LucyRx," said David Blair, CEO of LucyRx. "We're combining two organizations who are relentlessly focused on performance, innovation and compassion, and continually raising the bar for what clients and members can expect from a PBM." "We're proud of the foundation CerpassRx has built, and we believe LucyRx is the right partner to take it even further," said Mark Newman, CEO and Co-Founder of Nomi Health. "This agreement reflects a shared vision for more transparent, tech-forward pharmacy care and we're confident it will create long-term value for clients, members, and the broader market." "Clients expect more from their PBM, and they should," said Susan Thomas, Chief Commercial Officer at LucyRx. "Together with CerpassRx, we expand both the reach and depth of our solutions. And we'll deliver an experience that is more personal, more affordable and more clinically impactful." "Joining LucyRx is a natural next step for our clients and our team," said John Nicolosi, PharmD, Interim President of CerpassRx. "Our shared values of clarity, accountability, and care make this a powerful combination. We're excited to extend our impact with the support of LucyRx's technology, scale, and clinical approach." What Clients and Members Can Expect There will be no changes to service, support, or operations as a result of this agreement. Clients and members will continue to receive the same high-quality care and responsiveness they've come to expect from both organizations. This move builds on LucyRx's momentum as a PBM committed to doing things differently, with an emphasis on clarity, clinical rigor, and measurable outcomes. As part of this agreement, Nomi Health and LucyRx will continue working together to support their shared clients and build on current partnership efforts to reduce pharmacy costs for both employers and their members, advancing a shared commitment to bring more transparency, innovation, and affordability to healthcare. About LucyRx LucyRx is fast-scaling, independent, next-generation pharmacy benefit manager (PBM) redefining prescription care. Fueled by innovation and decades of leadership experience, LucyRx delivers better outcomes through its integrated specialty network, formulary marketplace, and next-day home delivery solutions. Powered by its proprietary AI platform, LucyIQ™, the company provides real-time insights that support evidence-based clinical decisions, clear pricing, and exceptional service from U.S.-based pharmacy technicians. Partnering with more than 60,000 pharmacies, LucyRx serves over 1,200 clients nationwide. This is prescription care, brilliantly reimagined. Learn more at About CerpassRx CerpassRx is a leading, full-service, pharmacy benefit manager based in Dallas-Fort Worth, Texas. Its services include prescription optimization, flexible formulary designs, personalized member support, and efficient mail and specialty pharmacy programs. Committed to driving efficiency and enhancing pharmacy benefit management, CerpassRx helps clients navigate the complexities of prescription care. For more information, visit About Nomi Health Nomi Health is rebuilding healthcare through its direct model. Founded in 2019, the company's integrated platform combines analytics, direct provider networks, and real-time payment solutions - providing the infrastructure that powers better healthcare. The company serves 4,000 customers nationwide, impacting 30 million lives and influencing over $200 billion in healthcare spend. Based in Orem, Utah, Nomi Health leads the movement to rebuild America's healthcare system. Learn more at View source version on Contacts Media Contact for LucyRx Tricia Bancroft516-241-6157press@ Strategic Partnerships Contact at LucyRx Alex Motola, Chief Business Officer and Head of M&Aamotola@ Media Contact for Nomi Health Rebeca Damico385-887-1641rebeca@ Sign in to access your portfolio
Yahoo
5 minutes ago
- Yahoo
Howmet Aerospace Posts Record Profit, Raises 2025 Outlook
Howmet Aerospace Inc. (NYSE:HWM) announced its second-quarter 2025 financial results on Thursday. The company exceeded all guidance and strengthened its position in the aerospace and defense sectors. The company reported record revenue and profit, driven by robust demand, prompting an upward revision of its full-year 2025 outlook. Howmet Aerospace achieved record revenue of $2.05 billion, a 9% year-over-year increase, fueled by strong growth in commercial aerospace (up 8%), defense aerospace (up 21%), and industrial and other markets (up 17%), surpassing consensus estimates of $2.007 Income reached $407 million, or $1.00 per share. Adjusted earnings per share rose 36% year over year to 91 cents, beating the consensus estimate of 87 cents. Adjusted EBITDA (excluding special items) surged 22% to $589 million, with the margin expanding 300 basis points to 28.7%. Adjusted operating income margin expanded 330 bps to 25.3%. The company generated a record $344 million in free cash flow, marking its ninth consecutive positive quarter. Operating cash flow totaled $446 million, with a quarter-end cash balance of $546 million. In the second quarter, Engine Products led segment performance with a 13% year-over-year revenue increase to $1.1 billion, fueled by strength in aerospace, industrial gas turbines, and the oil and gas markets. The segment delivered a 20% rise in adjusted EBITDA, reaching $349 million, representing a healthy margin of 33.0%. Fastening Systems followed with a 9% revenue increase to $431 million, supported by robust demand in both commercial and defense aerospace. Adjusted EBITDA for the segment climbed 25% to $126 million, translating to a margin of 29.2%. Engineered Structures saw revenue grow 5% to $290 million, primarily driven by gains in defense aerospace. The segment's adjusted EBITDA surged 55% to $62 million, reflecting a margin of 21.4%, the strongest year-over-year EBITDA growth among all divisions. View more earnings on HWM Meanwhile, Forged Wheels was the only segment to post a decline in revenue, which edged down 1% to $276 million due to softer commercial transportation volumes. However, this was partially offset by favorable aluminum cost pass-throughs. Despite the top-line pressure, the segment's adjusted EBITDA rose 1% to $76 million, yielding a 27.5% margin. Howmet Aerospace repurchased $175 million of common stock in the quarter and an additional $100 million in July 2025. Year-to-date, $400 million in stock has been repurchased, with $1.797 billion remaining under authorization. The Board increased the quarterly common stock dividend by 20% to 12 cents per share, to be paid on August 25, 2025, to holders of record as of the close of business on August 8, 2025 The company also paid down $76 million of its U.S. dollar-denominated Term Loan, reducing annualized interest expense and bringing the net debt-to-LTM EBITDA ratio to a record low of 1.3x. Howmet Aerospace Executive Chairman and Chief Executive Officer John Plant commented, 'Turning to the outlook, the commercial aerospace market should continue to grow, driven by healthy passenger traffic, extraordinarily high OEM backlogs and the desire for new, fuel-efficient aircraft. We acknowledge positive signs for narrow body build rate increases, particularly on the Boeing 737MAX. Demand for engine spares also remains robust across all markets. The defense aerospace market continues to show strength that should carry through 2025.' 'Additionally, demand for industrial gas turbines fueled by significant data center expansion should remain strong for the balance of the year. The commercial transportation market remains weak. Taking these factors into account, the overall picture appears healthy, and we are increasing our full year 2025 guidance on all metrics.' Outlook For the third quarter, the company expects revenue between $2.02 billion and $2.04 billion versus the consensus of $2.027 billion, with adjusted earnings per share projected between 89 and 91 cents versus the consensus of 87 cents. Adjusted EBITDA is forecast between $575 million and $585 million, representing a margin of 28.5% to 28.7%. The company raised its full-year 2025 outlook, now expecting revenue of $8.08 billion to $8.18 billion, up $100 million from the prior baseline versus the consensus of $8.084 billion. Adjusted EPS is projected at $3.56 to $3.64, a 20-cent increase versus the consensus of $3.51. Adjusted EBITDA is guided between $2.3 billion and $2.34 billion, up $70 million, with a margin of approximately 28.5% to 28.6%, up 50 basis points. Free cash flow is now expected to range from $1.175 billion to $1.275 billion, an increase of $75 million. Price Action: HWM shares are trading lower by 6.53% to $179.75 at Thursday's last check. Read Next:Photo by T. Schneider via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Howmet Aerospace Posts Record Profit, Raises 2025 Outlook originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 minutes ago
- Yahoo
Seth Meyers Roasted Karoline Leavitt In A Comedy Bit About What Trump Shockingly Called His "Past" Supporters
White House press secretary Karoline Leavitt left Seth Meyers baffled during a spoof press briefing on NBC's Late Night Tuesday. In the latest installment of the recurring comedy segment — which uses clever editing to insert Meyers into mock exchanges with Leavitt ― the host asked her to respond to President Donald Trump calling his supporters 'weaklings' for demanding the release of the Epstein files. Related: 'That claim is just simply untrue,' Leavitt replied. 'What? He posted it on social media last week,' Meyers shot back. Related: What followed was a looping exchange of contradictions, with Leavitt denying Trump ever made the comment while also acknowledging he had. Related: The back-and-forth ended with Meyers exasperatedly saying, 'Oh, my God! Why are you like this?!?' Leavitt's final response? 'There really isn't a good explanation for that.' Related: Watch here: This article originally appeared on HuffPost. Also in In the News: Also in In the News: Also in In the News:
